817 related articles for article (PubMed ID: 8589724)
21. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
[TBL] [Abstract][Full Text] [Related]
22. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.
Horny HP; Sotlar K; Valent P
Pathobiology; 2010; 77(4):169-80. PubMed ID: 20616612
[TBL] [Abstract][Full Text] [Related]
23. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma.
Kim Y; Weiss LM; Chen YY; Pullarkat V
Leuk Res; 2007 Dec; 31(12):1749-54. PubMed ID: 17544505
[TBL] [Abstract][Full Text] [Related]
24. Urticaria pigmentosa.
Brockow K
Immunol Allergy Clin North Am; 2004 May; 24(2):287-316, vii. PubMed ID: 15120152
[TBL] [Abstract][Full Text] [Related]
25. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
[TBL] [Abstract][Full Text] [Related]
26. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.
Zappulla JP; Dubreuil P; Desbois S; Létard S; Hamouda NB; Daëron M; Delsol G; Arock M; Liblau RS
J Exp Med; 2005 Dec; 202(12):1635-41. PubMed ID: 16352739
[TBL] [Abstract][Full Text] [Related]
27. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
[TBL] [Abstract][Full Text] [Related]
28. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.
Valent P; Ghannadan M; Akin C; Krauth MT; Selzer E; Mayerhofer M; Sperr WR; Arock M; Samorapoompichit P; Horny HP; Metcalfe DD
Eur J Clin Invest; 2004 Aug; 34 Suppl 2():41-52. PubMed ID: 15291805
[TBL] [Abstract][Full Text] [Related]
29. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
30. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
31. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
32. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.
Jordan JH; Fritsche-Polanz R; Sperr WR; Mitterbauer G; Födinger M; Schernthaner GH; Christian Bankl H; Gebhart W; Chott A; Lechner K; Valent P
Leuk Res; 2001 Jul; 25(7):627-34. PubMed ID: 11377687
[TBL] [Abstract][Full Text] [Related]
33. Current state of biology and diagnosis of clonal mast cell diseases in adults.
Alvarez-Twose I; Morgado JM; Sánchez-Muñoz L; García-Montero A; Mollejo M; Orfao A; Escribano L
Int J Lab Hematol; 2012 Oct; 34(5):445-60. PubMed ID: 22551157
[TBL] [Abstract][Full Text] [Related]
34. The biology of Kit in disease and the application of pharmacogenetics.
Akin C; Metcalfe DD
J Allergy Clin Immunol; 2004 Jul; 114(1):13-9; quiz 20. PubMed ID: 15241338
[TBL] [Abstract][Full Text] [Related]
35. Neonatal mastocytosis with pachydermic bullous skin without c-Kit 816 mutation.
Walker T; von Komorowski G; Scheurlen W; Dorn-Beineke A; Back W; Bayerl C
Dermatology; 2006; 212(1):70-2. PubMed ID: 16319478
[TBL] [Abstract][Full Text] [Related]
36. Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations.
Fett NM; Teng J; Longley BJ
Am J Dermatopathol; 2013 Feb; 35(1):113-6. PubMed ID: 22892471
[TBL] [Abstract][Full Text] [Related]
37. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
Akin C
J Mol Diagn; 2006 Sep; 8(4):412-9. PubMed ID: 16931579
[TBL] [Abstract][Full Text] [Related]
38. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
39. Clonality and molecular pathogenesis of mastocytosis.
Akin C
Acta Haematol; 2005; 114(1):61-9. PubMed ID: 15995326
[TBL] [Abstract][Full Text] [Related]
40. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
